Search - tctmd.com

Displaying 301 - 320 of 417

Sort: Relevancy | Date

Presentation TCT 2016

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Stephan Windecker

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Tricuspid Valve Repair Technologies

Presenter: John G. Webb, Ajit Yoganathan, Scott Lim

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Mitral Valve Replacement and Repair Technologies

Presenter: John G. Webb, Ajit Yoganathan, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

The TAVR Development Journey: Lessons Learned and Drivers of Success

Presenter: John G. Webb, Ajit Yoganathan

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Aaron Chalekian

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, John G. Webb

October 30, 2016

Presentation TCT 2016

Animal Testing: Real-World Experiences and Translational Challenges

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Presenter: Patrick T. O'Gara, Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Animal Testing: FDA Expectations

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Natalie Miller

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Poor Femoral Access

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Richard Smalling

October 30, 2016

Advertisement

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Lessons Learned from Early FIH/EFS Trials: Tricuspid Valve Repair Technologies

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Lessons Learned from Early FIH/EFS Trials: Mitral Valve Replacement and Repair Technologies

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

The TAVR Development Journey: Lessons Learned and Drivers of Success

Intermediate-Risk Studies II: Updates From SURTAVI

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Animal Testing: Real-World Experiences and Translational Challenges

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Animal Testing: FDA Expectations

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

FDA Perspectives

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

TAVR in Patients With Poor Femoral Access

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content